UBE3D

Summary

UBE3D (ubiquitin protein ligase E3D, HGNC:21381) is a protein-coding gene on chromosome 6q14.1, encoding E3 ubiquitin-protein ligase E3D (Q7Z6J8). E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. It is a selective cancer dependency (DepMap: 11.5% of cell lines).

Enables cyclin binding activity; ubiquitin protein ligase activity; and ubiquitin-like protein conjugating enzyme binding activity. Involved in protein autoubiquitination; protein monoubiquitination; and protein polyubiquitination. Part of ubiquitin ligase complex. Is active in cytosol.

Source: NCBI Gene 90025 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 73 total
• Cancer dependency (DepMap): dependent in 11.5% of screened cell lines
• MANE Select transcript: NM_198920

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21381
Approved symbol	UBE3D
Name	ubiquitin protein ligase E3D
Location	6q14.1
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp434A1520, H10BH, YJR141W
Ensembl gene	ENSG00000118420
Ensembl biotype	protein_coding
OMIM	612495
Entrez	90025

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 5 nonsense_mediated_decay, 5 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000237186, ENST00000369746, ENST00000369747, ENST00000430071, ENST00000503942, ENST00000505226, ENST00000509102, ENST00000626828, ENST00000910309, ENST00000917834, ENST00000917835

RefSeq mRNA: 6 — MANE Select: NM_198920 NM_001304437, NM_001350602, NM_001350603, NM_001350604, NM_001410933, NM_198920

CCDS: CCDS34491, CCDS93953

Canonical transcript exons

ENST00000369747 — 10 exons

Exon	Start	End
ENSE00002050287	83065642	83065841
ENSE00003475133	83057826	83058022
ENSE00003489455	82957312	82957450
ENSE00003502521	82892390	82893042
ENSE00003568689	83018973	83019136
ENSE00003617859	83044428	83044659
ENSE00003624043	83054148	83054238
ENSE00003633480	83023969	83024038
ENSE00003650429	83038416	83038485
ENSE00003692750	83022453	83022561

Expression profiles

Bgee: expression breadth ubiquitous, 231 present calls, max score 93.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.6539 / max 233.9773, expressed in 1681 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
74549	7.1123	1654
74548	1.4711	515
74547	0.0705	31

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	93.20	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.92	gold quality
bronchial epithelial cell	CL:0002328	83.61	gold quality
bronchus	UBERON:0002185	82.27	gold quality
right uterine tube	UBERON:0001302	81.67	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	79.44	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.64	gold quality
caudate nucleus	UBERON:0001873	78.18	gold quality
hypothalamus	UBERON:0001898	77.81	gold quality
oviduct epithelium	UBERON:0004804	77.81	gold quality
putamen	UBERON:0001874	77.15	gold quality
Brodmann (1909) area 9	UBERON:0013540	77.10	gold quality
islet of Langerhans	UBERON:0000006	76.77	gold quality
cortical plate	UBERON:0005343	76.47	gold quality
calcaneal tendon	UBERON:0003701	75.95	gold quality
colonic epithelium	UBERON:0000397	75.94	gold quality
right frontal lobe	UBERON:0002810	75.78	gold quality
fallopian tube	UBERON:0003889	75.60	gold quality
nucleus accumbens	UBERON:0001882	75.57	gold quality
anterior cingulate cortex	UBERON:0009835	75.53	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	75.31	gold quality
prefrontal cortex	UBERON:0000451	75.30	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	75.20	gold quality
body of pancreas	UBERON:0001150	75.11	gold quality
mucosa of paranasal sinus	UBERON:0005030	75.10	gold quality
pancreas	UBERON:0001264	75.00	gold quality
palpebral conjunctiva	UBERON:0001812	74.95	gold quality
cerebellar hemisphere	UBERON:0002245	74.54	gold quality
cerebellar cortex	UBERON:0002129	74.39	gold quality
amygdala	UBERON:0001876	74.34	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.43

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

43 targeting UBE3D, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-7159-5P	99.53	72.12	2472
HSA-MIR-106A-3P	99.53	67.58	995
HSA-MIR-543	99.52	69.03	2595
HSA-MIR-136-5P	99.50	67.26	1153
HSA-MIR-142-5P	99.48	70.92	2416
HSA-MIR-5590-3P	99.48	70.91	2429
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-942-5P	99.41	68.40	1977
HSA-MIR-584-3P	99.35	67.69	1082
HSA-MIR-4427	99.34	70.33	1854
HSA-MIR-4279	99.19	66.70	2437
HSA-MIR-548L	99.06	70.90	2560
HSA-MIR-511-5P	98.97	70.94	2268
HSA-MIR-1294	98.91	69.26	1030
HSA-MIR-9986	98.91	69.28	1024
HSA-MIR-382-3P	98.83	67.10	1074
HSA-MIR-501-5P	98.77	68.88	1328

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 11.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• The carboxyl terminal half of H10BH was able to bind cyclin B and ubiquitinylate cyclin B in vitro. (PMID:15749827)
• A novel missense SNV, rs7739323, is strongly associated with age-related macular degeneration in an East Asian population. (PMID:25872646)
• With the exception of associations of BEGAIN with severe and UBE3D with moderate chronic periodontitis (CP) , no other loci were associated with CP in ARIC or aggressive periodontitis in the German sample. (PMID:26962152)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ube3d	ENSDARG00000026178
mus_musculus	Ube3d	ENSMUSG00000032415
rattus_norvegicus	Ube3d	ENSRNOG00000010802
caenorhabditis_elegans		WBGENE00022168

Protein

Protein identifiers

E3 ubiquitin-protein ligase E3D — Q7Z6J8 (reviewed: Q7Z6J8)

Alternative names: HECT-type E3 ubiquitin transferase E3D, UbcH10-binding protein with a HECT-like domain, Ubiquitin-conjugating enzyme E2C-binding protein

All UniProt accessions (6): Q7Z6J8, D6RD24, D6RHY9, H0Y359, J3KMY4, Q4G0X5

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Independently of its E3 ubiquitin-protein ligase activity, acts as an inhibitor of CPSF3 endonuclease activity by blocking CPSF3 active site.

Subunit / interactions. Interacts with UBE2C/UbcH10 (E2 ubiquitin-conjugating enzyme). In vitro, interacts with cyclin-B.

Subcellular location. Cytoplasm.

Post-translational modifications. Ubiquitinated by UBCH10 (E2 ubiquitin-conjugating enzyme).

Domain organisation. The C-terminal half (AA 188-389) is able to bind cyclin-B and shows a self-ubiquitination activity (mono-, poly, or multi-ubiquitination) in a HECT-like sequence dependent manner. The BRAT1-like motif mediates inhibition of the endonuclease activity of CPSF3 by forming hydrogen bond and hydrophobic interactions with the active site of CPSF3: Cys-144 coordinates one of the two active site zinc ions of CPSF3.

Pathway. Protein modification; protein ubiquitination.

RefSeq proteins (6): NP_001291366, NP_001337531, NP_001337532, NP_001337533, NP_001397862, NP_944602* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019193	UBQ-conj_enz_E2-bd_prot	Family

Pfam: PF09814

UniProt features (11 total): sequence conflict 2, region of interest 2, sequence variant 2, initiator methionine 1, chain 1, short sequence motif 1, binding site 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z6J8-F1	79.34	0.51

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 144

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation

MSigDB gene sets: 122 (showing top): REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_PROTEIN_AUTOUBIQUITINATION, TGIF_01, GOBP_PROTEIN_MONOUBIQUITINATION, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_PROTEIN_POLYUBIQUITINATION, STONER_ESOPHAGEAL_CARCINOGENESIS_DN, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS, RIGGI_EWING_SARCOMA_PROGENITOR_UP, GOBP_PROTEIN_CATABOLIC_PROCESS, GOCC_TRANSFERASE_COMPLEX, GOBP_PROTEOLYSIS

GO Biological Process (5): protein polyubiquitination (GO:0000209), protein monoubiquitination (GO:0006513), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), protein autoubiquitination (GO:0051865), protein ubiquitination (GO:0016567)

GO Molecular Function (7): ribonuclease inhibitor activity (GO:0008428), cyclin binding (GO:0030332), ubiquitin conjugating enzyme binding (GO:0031624), ubiquitin-like protein conjugating enzyme binding (GO:0044390), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740)

GO Cellular Component (4): ubiquitin ligase complex (GO:0000151), nucleus (GO:0005634), cytosol (GO:0005829), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Class I MHC mediated antigen processing & presentation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein ubiquitination	3
cellular anatomical structure	2
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
protein modification by small protein conjugation	1
RNA nuclease activity	1
nuclease inhibitor activity	1
protein binding	1
ubiquitin-like protein conjugating enzyme binding	1
enzyme binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
intracellular protein-containing complex	1
transferase complex	1
intracellular membrane-bounded organelle	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

492 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
UBE3D	UBE2C	O00762	935
UBE3D	CBLL2	Q8N7E2	589
UBE3D	ARIH2	O95376	524
UBE3D	PUDP	Q08623	450
UBE3D	C6orf163	Q5TEZ5	447
UBE3D	CSTF3	Q12996	443
UBE3D	FBXO42	Q6P3S6	428
UBE3D	NOL9	Q5SY16	396
UBE3D	FCF1	Q9Y324	392
UBE3D	CPSF3	Q9UKF6	391
UBE3D	RWDD2A	Q9UIY3	386
UBE3D	SNAPC3	Q92966	384
UBE3D	CEP162	Q5TB80	377
UBE3D	ZNF668	Q96K58	377
UBE3D	SMIM8	Q96KF7	373

IntAct

34 interactions, top by confidence:

A	B	Type	Score
CCM2	KRIT1	psi-mi:“MI:0914”(association)	0.960
LMO1	ZBTB43	psi-mi:“MI:0914”(association)	0.830
DNAAF2	UBE3D	psi-mi:“MI:0914”(association)	0.780
UBE3D	DNAAF2	psi-mi:“MI:0915”(physical association)	0.780
DNAAF2	UBE3D	psi-mi:“MI:0915”(physical association)	0.780
CPSF3	CPSF4	psi-mi:“MI:0914”(association)	0.640
MAGEA11	UBE3D	psi-mi:“MI:0915”(physical association)	0.560
LMO3	ZBTB43	psi-mi:“MI:0914”(association)	0.550
DEFA1	MANBA	psi-mi:“MI:0914”(association)	0.530
FKBP6	EEF2K	psi-mi:“MI:0914”(association)	0.530
KLHDC2	PFDN1	psi-mi:“MI:0914”(association)	0.530
UBE3D	STIP1	psi-mi:“MI:0914”(association)	0.530
SLC31A1	C2orf72	psi-mi:“MI:0914”(association)	0.530
C1QTNF9B	PLOD3	psi-mi:“MI:0914”(association)	0.530
UBE3D	PPP5C	psi-mi:“MI:0915”(physical association)	0.400
CPSF3	P4HA2	psi-mi:“MI:0914”(association)	0.350
CCM2	KRIT1	psi-mi:“MI:0914”(association)	0.350
MEMO1	TARBP2	psi-mi:“MI:0914”(association)	0.350
CAPZB	ENAH	psi-mi:“MI:0914”(association)	0.350
TCTN2	TMEM131L	psi-mi:“MI:0914”(association)	0.350
NXPH1	RAD51C	psi-mi:“MI:0914”(association)	0.350
LCN9	C1QL1	psi-mi:“MI:0914”(association)	0.350
MEMO1	HMBOX1	psi-mi:“MI:0914”(association)	0.350
LMO1	LMX1B	psi-mi:“MI:0914”(association)	0.350
ATG101	FIBP	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (70): UBE3D (Affinity Capture-MS), UBE3D (Affinity Capture-MS), UBE3D (Affinity Capture-MS), DNAAF2 (Affinity Capture-MS), UBE3D (Affinity Capture-MS), GTPBP2 (Affinity Capture-MS), SUFU (Affinity Capture-MS), UBE3D (Affinity Capture-MS), HSP90AB4P (Affinity Capture-MS), UBE3D (Affinity Capture-MS), UBE3D (Affinity Capture-MS), UBE3D (Affinity Capture-MS), STIP1 (Affinity Capture-MS), BORA (Affinity Capture-MS), TUBA4A (Affinity Capture-MS)

ESM2 similar proteins: A1KXW8, A6QL50, E1BGQ2, H0Y354, O94955, P47224, Q08326, Q0IIH8, Q1JQA1, Q1RMS8, Q1RMZ1, Q2TBU5, Q3T1H6, Q4R372, Q4R528, Q4R9C4, Q5F480, Q5F4A1, Q5I0G3, Q5RCQ0, Q5RFG8, Q5TFE4, Q5TYM5, Q641X7, Q6L9T8, Q6PIP5, Q7L622, Q7Z6J8, Q7ZX59, Q86X60, Q8BFZ8, Q8BKW4, Q8BM85, Q8BX13, Q8CEL2, Q8N5C7, Q8N635, Q8NHU2, Q8TCF1, Q8TCJ0

Diamond homologs: Q1JQA1, Q3T1H6, Q5RFG8, Q7Z6J8, Q8BX13

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

73 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	57
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3605 predictions. Top by Δscore:

Variant	Effect	Δscore
6:82936951:AGGT:A	donor_gain	1.0000
6:83022560:ACC:A	acceptor_loss	1.0000
6:83024039:C:CC	acceptor_gain	1.0000
6:83040612:ATT:A	donor_gain	1.0000
6:83057824:A:AC	donor_gain	1.0000
6:83057825:C:CC	donor_gain	1.0000
6:83065640:ACC:A	donor_gain	1.0000
6:83065641:CCC:C	donor_gain	1.0000
6:82893962:AC:A	donor_gain	0.9900
6:82893963:CC:C	donor_gain	0.9900
6:82936951:A:AC	donor_gain	0.9900
6:82936952:G:C	donor_gain	0.9900
6:82957306:GCTCA:G	donor_loss	0.9900
6:82957307:CTCAC:C	donor_loss	0.9900
6:82957308:TCACC:T	donor_loss	0.9900
6:82957309:CAC:C	donor_loss	0.9900
6:82957310:A:AG	donor_loss	0.9900
6:82957311:C:CA	donor_loss	0.9900
6:82957446:CAAGT:C	acceptor_gain	0.9900
6:82957451:C:CC	acceptor_gain	0.9900
6:83019132:CATAG:C	acceptor_gain	0.9900
6:83022447:TCTTA:T	donor_loss	0.9900
6:83022448:CTTA:C	donor_loss	0.9900
6:83022449:TTA:T	donor_loss	0.9900
6:83022450:TACCA:T	donor_loss	0.9900
6:83022451:A:G	donor_loss	0.9900
6:83022564:G:C	acceptor_loss	0.9900
6:83038410:TCTTA:T	donor_loss	0.9900
6:83038411:CTTAC:C	donor_loss	0.9900
6:83038412:TTAC:T	donor_loss	0.9900

AlphaMissense

2549 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:83038458:A:G	C209R	0.988
6:83054182:A:G	C111R	0.985
6:83054180:G:C	C111W	0.983
6:83019133:A:G	W284R	0.980
6:83019133:A:T	W284R	0.980
6:83044601:A:G	W142R	0.980
6:83044601:A:T	W142R	0.980
6:83019004:A:C	Y327D	0.979
6:82957379:A:G	L361P	0.978
6:83019009:A:T	V325D	0.978
6:83038449:A:G	C212R	0.975
6:83038456:A:C	C209W	0.975
6:83054173:A:G	C114R	0.975
6:83038448:C:G	C212S	0.974
6:83038449:A:T	C212S	0.974
6:83022489:G:C	F270L	0.973
6:83022489:G:T	F270L	0.973
6:83022490:A:G	F270S	0.973
6:83022491:A:G	F270L	0.973
6:83038457:C:T	C209Y	0.973
6:83019011:C:A	K324N	0.972
6:83019011:C:G	K324N	0.972
6:83022495:A:C	F268L	0.971
6:83022495:A:T	F268L	0.971
6:83022497:A:G	F268L	0.971
6:83054172:C:T	C114Y	0.970
6:83038433:C:T	G217E	0.969
6:83038457:C:G	C209S	0.969
6:83038458:A:T	C209S	0.969
6:82957437:A:G	W342R	0.968

dbSNP variants (sampled 300 via entrez): RS1000019849 (6:83056922 A>G), RS1000030866 (6:83009595 A>G), RS1000032400 (6:82921211 C>T), RS1000074211 (6:83015068 C>G), RS1000121421 (6:82928801 A>G), RS1000129946 (6:82943004 G>A), RS1000135404 (6:82951150 A>G), RS1000164450 (6:83000448 C>A,G), RS1000174916 (6:82989536 C>T), RS1000175441 (6:82992286 G>A,C,T), RS1000192978 (6:82958806 A>G,T), RS1000200839 (6:83044208 G>C), RS1000207826 (6:82903004 T>C), RS1000208453 (6:82905357 A>G,T), RS1000210533 (6:83032887 C>A,T)

Disease associations

OMIM: gene MIM:612495 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST003360_3	Crohn’s disease	2.000000e-11
GCST003901_8	Cognitive decline (age-related)	1.000000e-06
GCST006288_130	Heel bone mineral density	5.000000e-12
GCST006288_553	Heel bone mineral density	5.000000e-13
GCST006979_299	Heel bone mineral density	2.000000e-33
GCST009177_5	Entorhinal cortical volume	9.000000e-06
GCST010988_368	Adult body size	5.000000e-09
GCST012291_7	Schizophrenia, bipolar disorder or recurrent major depressive disorder	3.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0009270	heel bone mineral density
EFO:0005092	entorhinal cortical volume
EFO:0004952	disease recurrence

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects cotreatment, decreases expression, affects expression	7
mercuric bromide	decreases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
Tretinoin	decreases expression	2
bisphenol F	affects cotreatment, increases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	increases expression	1
trichostatin A	decreases expression	1
beta-lapachone	decreases expression	1
sodium arsenite	decreases expression	1
zinc chromate	affects expression, increases abundance	1
benzo(e)pyrene	increases methylation	1
chromium hexavalent ion	affects expression, increases abundance	1
entinostat	increases expression	1
monomethylarsonous acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	increases methylation	1
Sunitinib	increases expression	1
Vorinostat	increases expression	1
Acetaminophen	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	decreases expression	1
Calcitriol	affects cotreatment, decreases expression	1
Dexamethasone	increases expression, affects cotreatment	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Indomethacin	increases expression, affects cotreatment	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.